Moody's ups Abbott outlook to stable

Moody's Investors Service said it changed the outlook of Abbott Laboratories to stable from negative.

At the same time, Moody's said it affirmed Abbott's A1 long-term debt ratings and its prime-1 short-term rating.

Moody's noted that the change in outlook primarily reflects our expectation that: (1) Abbott will generate stronger cash flow in 2008 supported by new products such as Xience and Simcor as well as continued expansion of Humira and (2) in combination with somewhat lower risk of large acquisitions over the near-term, cash balances and credit metrics should improve.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.